Vitamin D3 for Life

Live Enlightened

Physiology

Infant Vitamin D, Bone, Minerals and Health Outcomes: Study Summary

Previous related pageInfant Vitamin D, Bone, Minerals and Health Outcomes: Full Evidence ReviewNext related pageInfant Vitamin D, Bone, Minerals and Health Outcomes: Full Evidence Review
Study at a glance

What was studied?

Researchers tested whether vitamin D strategies changed infant bone measurements, blood minerals, rickets (a disorder of growing bone), reported infections or body composition. The trials involved different populations, including infants with low starting vitamin D status and infants born early.

What did the studies find?

Several trials in infants born at the usual stage of pregnancy raised vitamin D blood levels without demonstrating an added bone benefit. A maternal strategy given during pregnancy and continued after birth reduced cases meeting a laboratory definition of rickets in Bangladesh. This was not the same as X-ray-confirmed disease. A Finnish trial found no reduction in reported infections overall. One trial found modestly more lean tissue at 12 months, without showing stronger muscles or less body fat.

What does this mean?

Blood measurements, bone scans and diagnosed illness answer different questions. A benefit for one outcome does not establish benefit for all outcomes. Lean tissue includes soft tissue other than fat, including muscle; measuring its amount does not measure its strength.

What are the limits?

The studies used different doses, timing and populations. Some outcomes were uncertain or measured only in a small sample. Most infants in the Finnish trial already had sufficient vitamin D status. The findings do not establish a universal dose or blood target.

Read the full article below ↓

Raising an infant’s vitamin D blood level does not automatically improve every health outcome. This summary compares five independent trial groups that measured bone, mineral markers, rickets, reported infections or body composition. Their results include both benefits and findings of no detected added benefit. For the full assessment, read Infant Vitamin D, Bone, Minerals and Health Outcomes: Full Evidence Review.

What was measured?

Vitamin D status was usually assessed with 25-hydroxyvitamin D, written as 25(OH)D. This substance is produced when the body processes vitamin D. It is different from the vitamin D3 supplement and the active vitamin D hormone. The studies also measured health-related outcomes. A blood result, a bone scan and an illness diagnosis answer different questions. See Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D for the blood markers and Bone Mineralisation, Turnover and Fractures Measure Different Outcomes for the different bone measurements.

The supplement amounts describe research. They are not instructions for infant treatment. IU means international units. Infants born at term, meaning at the usual stage of pregnancy, differ from infants born early. Studies also differ in whether infants start with low vitamin D status or need specialist care.

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

Did higher doses improve bone measurements?

Gallo and colleagues compared four supplement amounts in 132 healthy breastfed infants born at term, meaning at the usual stage of pregnancy. Higher doses changed vitamin D status but did not show added growth or bone-mineral benefit. The highest-dose arm was stopped after high readings from one laboratory method; later results were lower and further safety checks were normal. This should not be described as proven toxic injury (Gallo et al., 2013).

The Finnish VIDI trial compared 400 with 1,200 IU daily in 975 infants included in its analysis. Most had sufficient status at birth. The higher dose raised blood levels but did not add a detected benefit in shin-bone measurements (Rosendahl et al., 2018).

Another Montreal trial selected 98 term infants with low vitamin D status at birth and assigned them by chance to 400 or 1,000 IU daily. It also found no demonstrated bone-mineral advantage from the higher amount. Its uncertainty was wide enough that the result should not be called proof that the two supplement amounts have the same effects (Gharibeh et al., 2023).

What about rickets?

A Bangladesh maternal supplementation trial produced a different finding. In a later analysis, 13 of 165 screened infants in the placebo group met a biochemical definition of rickets. Two of 154 met that definition in the group whose mothers received a higher-dose strategy during pregnancy and for six months after birth. All maternal groups also received calcium (Lautatzis et al., 2024).

Biochemical rickets means the study’s laboratory criteria were met. It is not the same as rickets confirmed on an X-ray. Across all groups, 39 infants met the biochemical definition, but only 16 had X-rays, and four of those had radiographic rickets. The result supports a reduction in the measured biochemical outcome under the tested maternal strategy. It does not identify a universal infant dose. Treatment of established disease is a different question, covered in Calcium Availability and Vitamin D Response in Nutritional Rickets: Full Study. The same parent trial did not show improved length at one year (Roth et al., 2018, corrected 2021).

Did other outcomes improve?

VIDI did not find fewer reported infections overall with the higher dose. The information came from parent diaries, not laboratory confirmation of each illness. This does not show that vitamin D has no immune function. It shows that the higher dose did not reduce this measured outcome in the infants studied.

The low-birth-status Montreal trial found modestly higher absolute lean mass with the higher dose at 12 months. It did not find a matching advantage in the proportion of lean tissue, lean mass adjusted for length, or fat outcomes. Lean mass includes soft tissue other than fat, including muscle. Measuring its amount is not a test of muscle strength. The finding does not establish better physical development or protection from obesity (Razaghi et al., 2022).

In 38 infants born early or with very low birthweight in Chiang Mai, 800 rather than 400 IU daily raised vitamin D status at six weeks of age. Calcium, phosphate and alkaline phosphatase, a protein that helps chemical reactions, did not show an added benefit. The trial was small and short, and it did not measure improved bone scans or fewer fractures (Rueang-Amnat et al., 2025).

What is the main limit?

The studies tested different populations, strategies and outcomes. A benefit in a deficient setting does not prove extra benefit in infants who already have sufficient status. A finding of no added bone benefit does not erase a biochemical-rickets benefit elsewhere. Unchanged blood minerals do not prove that mineral absorption or deposition in bone was unchanged.

The evidence supports separate conclusions for separate outcomes. It does not provide one best dose or blood target for every infant.

Sources

The detailed review uses these same assessed reports. Gharibeh and Razaghi describe one trial. The growth and rickets reports from Bangladesh also describe one trial. Unavailable supplementary material is not used to claim subgroup effects or complete safety.

Maternal Vitamin D Supplementation and Infantile Rickets: Secondary Analysis of a Randomized Trial. Lautatzis ME et al. Pediatrics. 2024;153:e2023063263.

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Roth DE et al. New England Journal of Medicine. 2018;379:535 to 546. Same MDIG trial; read with the 2021 correction.

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Correction. New England Journal of Medicine. 2021;385:1728. Parity coding and infant sex records corrected; not a separate trial.

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Related reading

Original sources

Source

Vitamins for children

For current UK guidance, see NHS Vitamins for children.

Publication details

For current UK guidance, see NHS Vitamins for children. Infants born early need advice from their neonatal team.

Read more →
Source

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Published in Gharibeh N et al. JAMA Pediatrics (2023).

Publication details

Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Gharibeh N et al. JAMA Pediatrics. 2023;177:353 to 362. DOI: 10.1001/jamapediatrics.2022.5837.

Read more →
Source

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial

Published in Razaghi M et al. American Journal of Clinical Nutrition (2022).

Publication details

Correction of neonatal vitamin D status using 1000 IU vitamin D/d increased lean body mass by 12 months of age compared with 400 IU/d: a randomized controlled trial. Razaghi M et al. American Journal of Clinical Nutrition. 2022;115:1612 to 1625. Same trial as Gharibeh; the title refers to correcting status, not an erratum.

Read more →